ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Recommend Approval Of Leucovorin, Hexamethylmelamine

June 16, 1989

ONCC Says 1,480 Nurses Passed Certification Exam

January 6, 1989

Telatinib Demonstrates Positive Results in First-Line Treatment

June 24, 2011

Biomedical Research Advocates Temper Budget Requests In View Of War, Deficit.

January 28, 2005

FDA says new tools needed to speed therapeutics development.

March 26, 2004

DCE Board Recompetition Concepts

July 17, 1987